AbstractHIVInternational Workshop on HIV Pediatrics 2021Impact of the COVID-19 pandemic on perinatal HIV prevention In Canada: Canadian Perinatal HIV Surveillance ProgramView Abstract
AbstractHIVInternational Workshop on HIV Pediatrics 2021Bone Mineral Density/Content of Postpartum Mothers Taking Treatment Including DTG Vs EFV, TDF Vs TAF in Pregnancy and Their Infants: Randomized IMPAACT 2010 TrialView Abstract
AbstractHIVInternational Workshop on HIV Pediatrics 2021Hypertensive Disorders in Pregnancy and HIV: A Province-Wide Cohort Analysis During 2018 and 2019 in the Western Cape, South AfricaView Abstract
AbstractHIVInternational Workshop on HIV Pediatrics 2021Longitudinal Study on Insulin Resistance and Metabolic Syndrome in Children with Perinatal HIV Infection and HIV Exposed Uninfected Children in South AfricaView Abstract
AbstractHIVInternational Workshop on HIV Pediatrics 2021Dolutegravir and Weight Gain to Adolescents Living with HIV at Baylor Mwanza-TanzaniaView Abstract
AbstractHIVInternational Workshop on HIV Pediatrics 2021Weight Gain in Children and Adolescents on Dolutegravir vs Standard-of-Care in the ODYSSEY TrialView Abstract
AbstractHIVInternational Workshop on HIV Pediatrics 2021Clinical Impact and Cost-Effectiveness of Viral Load Testing (VLT) to Inform the Transition to Pediatric Dolutegravir (DTG) in Antiretroviral Therapy (ART)-Experienced Children With HIV in South AfricaView Abstract
AbstractHIVInternational Workshop on HIV Pediatrics 2021Pharmacokinetics, Safety and Acceptability of a Single Dose of Abacavir/Lamivudine/Lopinavir/Ritonavir (4-In-1) Fixed-Dose Granule Formulation In Neonates: PETITE StudyView Abstract
AbstractHIVInternational Workshop on HIV Pediatrics 2021Pharmacokinetics and Safety of Dispersible- and Immediate-Release FDC Dolutegravir/Abacavir/Lamivudine in Children with HIV Weighing ≥14 kg: Preliminary Results from IMPAACT 2019View Abstract
AbstractHIVInternational Workshop on HIV Pediatrics 2021Long-term Safety & Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate (E/C/F/TAF) Single-Tablet Regimen in in Children and Adolescents Living with HIVView Abstract
AbstractHIVInternational Workshop on HIV Pediatrics 2021B/F/Taf in Virologically Suppressed Adolescents and Children: Two-Year Outcomes in 6 to <18 Year Olds And Six-Month Outcomes in ToddlersView Abstract
AbstractHIVInternational Workshop on HIV Pediatrics 2021Once-Daily Integrase Inhibitor (Insti) With Boosted Darunavir is Non-Inferior to Standard of Care in Virogically Suppressed Children, Week 48 Results of the Smile PENTA-17 TrialView Abstract
